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ABSTRACT
Objective to compare several methods of missing data 
imputation for function (Health assessment Questionnaire) 
and for disease activity (Disease activity Score-28 and 
clinical Disease activity index) in rheumatoid arthritis (ra) 
patients.
Methods One thousand ra patients from observational 
cohort studies with complete data for function and disease 
activity at baseline, 6, 12 and 24 months were selected to 
conduct a simulation study. Values were deleted at random 
or following a predicted attrition bias. three types of 
imputation were performed: (1) methods imputing forward 
in time (last observation carried forward; linear forward 
extrapolation); (2) methods considering data both forward 
and backward in time (nearest available observation—
naO; linear extrapolation; polynomial extrapolation); and 
(3) methods using multi-individual models (linear mixed 
effects cubic regression—lMe3; multiple imputation 
by chained equation—Mice). the performance of each 
estimation method was assessed using the difference 
between the mean outcome value, the remission and 
low disease activity rates after imputation of the missing 
values and the true value.
Results When imputing missing baseline values, all 
methods underestimated equally the true value, but lMe3 
and Mice correctly estimated remission and low disease 
activity rates. When imputing missing follow-up values 
at 6, 12, or 24 months, naO provided the least biassed 
estimate of the mean disease activity and corresponding 
remission rate. these results were not affected by the 
presence of attrition bias.
Conclusion When imputing function and disease activity 
in large registers of active ra patients, researchers can 
consider the use of a simple method such as naO for 
missing follow-up data, and the use of mixed-effects 
regression or multiple imputation for baseline data.
InTROduCTIOn
Large observational studies become more 
common for the assessment of new treat-
ments1 and are encouraged by national or 
international health agencies.2 Rheumatoid 
arthritis (RA) studies follows these trends 
and disease registers have been developed,3–8 
allowing to explore the effectiveness and safety 
of RA treatments in real-world populations. 
One of the key estimates of effectiveness is the 
calculation at a given follow-up time of the 
disease activity and the corresponding remis-
sion rate. However, observational register 
studies often face large amount of missing 
data, due to a variety of reasons, such as attri-
tion of patients over time or due to missing 
visits at specific follow-up periods. Missing 
data of a variable Y  can be of three type: (1) 
missing completely at random (MCAR) if 
the probability of missing is unrelated to any 
observed or unobserved variable, (2) missing 
Key messages
What is already known about this subject?
 ► Missing data is a major problem in large register of 
observational data. the use of complete case anal-
ysis is known to be a potential source of bias, and 
imputation of missing data is recommended.
What does this study add?
 ► the present work provides the first systematic study 
comparing the consequences of a wide range of 
strategies for dealing with missing values of function 
or disease activity in large registers of patients with 
rheumatoid arthritis (ra).
 ► imputation methods considering data both forward 
and backward in time, such as using the nearest 
available observation, give a mean value and an 
associated remission or low disease activity rates 
almost unbiased for missing follow-up.
How might this impact on clinical practice or 
future developments?
 ► the results presented will help researchers to ap-
propriately choose imputation methods when deal-
ing with missing function or disease activity data in 
large register of observational data. this will ease 
studies exploring the effectiveness and safety of ra 
treatments in real-world populations, and thus indi-
rectly impact clinical practices.
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at random (MAR) if the probability of missing depends 
on observed variables but not on missing values of Y  , and 
(3) missing not at random (MNAR) if the probability 
of missing depends on missing values of Y  .9 10 To avoid 
reducing the statistical power and to prevent the poten-
tial bias that complete case analyses (CCA) would cause 
in case of MAR or MNAR data,11 12 the use of imputation 
techniques to handle missing data is advised. Imputation 
methods available for longitudinal data are numerous. 
Some impute forward in time, such as last observation 
carried forward (LOCF) or linear forward extrapolation 
(LFE). Others consider data both forward and back-
ward in time, for instance nearest available observation 
(NAO),13 linear extrapolation (LE), and polynomial 
extrapolation (PE), where the missing data is obtained 
by the adjustment of the variable time dependence with a 
third order polynomial. More advanced methods use all 
available data from all patients. Mixed effects regression, 
for example, can be used as an imputation method by 
estimating the mean and the individual time evolution of 
disease activity to extrapolate missing data.14 Finally, the 
well-known multiple imputation using chained equation 
(MICE), uses data from other variables instead of using 
only the variable Y  at different time points.15 16 Despite 
the existence of this panel of techniques, an informal 
review of the articles using large registers published in 
two major rheumatology journals (Annals of the Rheumatic 
Diseases and Arthritis & Rheumatology) over the last 2 years 
demonstrated that almost 50% of them do not describe 
the strategy used to handle missing data, 25% use CCA 
and 5% LOCF. This observation, which is not specific to 
rheumatology,17 is partly due to the absence of guidelines 
and the lack of studies tackling the problem of data impu-
tation in large registers and its impact on outcomes esti-
mates. Although imputation has been studied in clinical 
trials of rheumatic diseases11 18–22 and in small registers,23 
the focus was generally limited to only a few imputation 
techniques and applied to a panel containing maximum 
four data points per patient. The aim of this work is thus 
to compare the effects of the main imputation techniques 
for MCAR or MAR data and the resulting impact on the 
estimation of mean function and disease activity and on 
the derived remission and low disease activity (LDA) 
rates in longitudinal observational data of RA patients. 
We will focus on the estimation of mean function and 
disease activity and remission rate at baseline and three 
specific but common follow-up: 6, 12 and 24 months.
MeTHOds
We used RA patient data from six national registries (Czech 
Republic, Denmark, Italy, Norway, Portugal and Sweden) 
of an existing register collaboration of RA registers (the 
Pan-European analysis of real-world effectiveness of abat-
acept (PanABA)).8 24 Each register has obtained ethical 
approval for the use of anonymous data for research in 
their local ethics committee. Inclusion criteria were diag-
nosis of RA established by a rheumatologist, >18 years of 
age and initiation of a treatment with abatacept or tumor 
necrosis factor-inhibitors. Baseline (0 month) was defined 
as the initiation of a bDMARD treatment, and follow-up 
as the time elapsed since treatment initiation. The three 
outcomes of interest were the Health Assessment Ques-
tionnaire (HAQ) and the disease activity score based on 
28 joints (DAS28) at four time points of interest: base-
line, 6, 12 and 24 months. Because in real world observa-
tional data, patients’ visits are rarely exactly at the speci-
fied time point, function and disease activity scores were 
taken within a time window from 0 to +1 month for base-
line or treatment initiation, and within a 3-month time 
window centred at the time of interest for follow-up visits 
(6, 12, or 24 months).
Creation of the two datasets for the simulation study
First, a random sample of 1000 patients were selected 
from a pool of patients with complete data for the three 
outcomes at 0, 6, 12 and 24 months (DS1). The patients 
selected in for this simulation study had more visits on 
average (median 20, IQR 8–25) than patients from the 
registers not included in this study (median 6, IQR 2–7). 
In order to study the behaviour of imputation methods on 
a dataset representative of patients a commonly followed 
in registers, we created a second dataset DS2 with a 
number of visits per patient similar to the average patient 
in the registers. To this end, we randomly selected for 
each patient of DS1 a number of visits following the prob-
ability density function of the overall dataset of 49 319 
patient stemming from 13 different countries (online 
supplementary figure S1). This procedure ensures that 
the DS2 dataset contained patients with similar visit 
numbers as the entire register collection. Main simula-
tions were performed on DS2, while sensitivity analysis 
on availability of data near follow-up were performed on 
DS1 (see Sensitivity analysis section).
Creating missing data
For each follow-up time of interest, missing data in the 
two datasets were created by deleting all data in a given 
time window centred on the time of imputation for a 
number of patients corresponding to a predetermined 
percentage of missing data (eg, 60% missing data at 6 
months, corresponds to 600 patients having no data 
available in a time windows centred on 6 months). The 
percentage of missing data at each time of imputation 
was varied from 10% to 90%. To simulate MCAR missing 
data, patients having missing data were chosen randomly, 
independently of any other variable. To simulate MAR 
missing data, patients with missing data were chosen by 
sampling them with a probability given by the odds of 
having a missing value for the considered outcome and 
follow-up time. For each outcome and follow-up, these 
odds were extracted from a generalised linear model 
applied on the entire register estimating the probability 
of having a missing outcome as a function of the treat-
ment duration, the number of previous biological treat-
ments and the baseline value of disease activity.
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sensitivity analysis
The length of time windows for the deletion of all obser-
vations used to create missing data was set to 3 months. As 
imputation performance may depend on the proximity 
of available data near follow-up, we varied the length of 
the time windows for deletions from 3 to 6 months, 12 
months (only for 12 and 24 months follow-up to avoid 
deleting baseline data) and 18 months (for 24 months 
follow-up) when creating missing data in DS1.
Imputation methods
Schematic of the imputation methods is presented in 
online supplementary figure S2.
last observation carried forward
LOCF sets the missing data to the last available value for 
each patient.
linear forward extrapolation
LFE assumes a linear trend between the missing data and 
the last two available data. The predicted value  Y
(
t
)
  of 
variable Y  at follow-up  t is:
 Y
(
t
)
=
Y
(
t−1
)−Y(t−2)
t−1−t−2
(
t− t−1
)
+ Y
(
t−1
)
 
where  t−1  is the last time with available data for Y  and 
 t−2  the second last one.
nearest available observation
NAO sets the missing data as equal to the closest available 
data in time (backward or forward) for each patient.
linear extrapolation
LE assumes a linear trend between the missing data 
and the two closest available data in time. Mathematical 
expression is the same as LFE with  t−1  the closest time 
with available data for Y  and  t−2  the second closest.
Polynomial extrapolation
PE adjusts the individual variable Y  with a K order time 
polynomial (for N measures,  K = N− 1 and K < 4 ), and 
predict the Y  missing value by calculating its value at 
follow-up  t :
 Y
(
t
)
= a + b1∗t + b2∗t2 + b3∗t3 
with a, b1, b2 and b3 the polynomial coefficients esti-
mated using ordinary least square regression.
linear mixed effects cubic regression
LME3 is a linear mixed effects model adjusting the vari-
able to be imputed by a third order polynomial of time 
using all patients together. Considering  Yi  the variable 
vector with the missing data and  ti  the time vector associ-
ated for patient  i , the regression reads:
 Yi ∼ b0 + u0i +
(
b1 + u1i
)
ti +
(
b2 + u2i
)
t2i +
(
b3 + u3i
)
t3i  
with  bn  the fixed effect coefficients and  uni  their random 
counterpart. The missing data at follow-up  t is predicted 
by directly estimating Y  for each patient at  t from the 
regression result.25 26
Multiple imputation by chained equation
Multiple imputation is a widely used technique of imputa-
tion developed by Rubin27 28 based on a Monte Carlo tech-
nique in which the dataset with missing value is replaced 
by m > 1 complete dataset. We used here MICE16 with 
the predictive mean matching technique implemented 
in the mice library in R with  nit = 10  iterations. Due to the 
high computational power required for our simulation, 
we chose m so that the SD of the imputation is only 1% 
wider than the one obtained with an infinite number of 
imputation28:
 m =
REλ
1−RE ≈ 100λ 
with λ being the rate of missing information, and RE 
the relative efficiency here set to 1%. It resulted in m 
varying between 22 and 35 depending on the parame-
ters. In this simulation study, the variables used for the 
imputation were time elapsed since treatment initiation, 
age, sex, patient identifier, number of previous biological 
DMARD, type of concomitant synthetic DMARD, disease 
duration, seropositivity and when imputing at time 
different than baseline, the baseline values of DAS28 and 
HAQ.
As sensitivity analysis, other MICE methods were tried 
for missing values set at 60%: Bayesian linear regression, 
random sample from observed values, random forest 
imputations. Influence of iteration and imputation 
number has been tested by increasing both the imputa-
tion number ( m = 50 ) and the iteration number ( nit = 50
 ).
complete case analysis
We also presented results based on CCA, for example, 
restricting results to follow-up with no missing values.
aberrant values
When imputing with LE, LFE or PE and if the imputed 
value was negative or above maximal possible value, it 
was set to 0 or the maximum value respectively. Following 
recommendations,29 imputed value of MICE were not 
changed.
simulation
For each condition of missing data, follow-up, 
percentage of missing data at follow-up and size of the 
deletion time windows, the values of the outcomes were 
deleted and imputed with each imputation method 
1000 times. Simulation was performed on the high 
performance computing facility of the Geneva Univer-
sity.
statistical methods
For each parameter condition, the mean value and the 
relative bias for the DAS28 and HAQ were calculated and 
averaged over the 1000 runs of the simulation. The rela-
tive bias for a value α is
 
∆α
α =
αimputed−αtrue
αtrue  
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Figure 1 Mean disease activity score based on 28 joints 
(left panel) and corresponding remission rate (right panel) of 
the data panel where the 60% of data missing completely 
at random at follow-up were handled with complete case 
analysis (CCA), last observation carried forward (LOCF), 
linear forward extrapolation (LFE), nearest available 
observation (NAO), linear extrapolation (LE), polynomial 
extrapolation (PE), linear mixed effect cubic regression 
(LME3) and multiple imputation by chained equation (MICE). 
Error bars are the standard errors calculated over the 1000 
simulation samples. LFE and LOCF estimation are missing 
for t=0 since these methods use previous values, which do 
not exist at baseline. Black horizontal lines represent the true 
values for each follow-up.
In addition, for DAS28, the percentage of remission and 
of LDA was also computed to better assess the potential 
clinical impact of the different imputation techniques.
R 3.6.130 software with the libraries lme4, mice, parallel, 
ggplot2 and  data. table were used to conduct the study. The 
code is provided as a supplementary file and can be used 
to implement these imputation techniques.
ResulTs
data MCAR
Mean imputed values
For missing baseline values, all imputation methods 
underestimated the true mean value of DAS28 (figure 1, 
left panel and online supplementary table S1) and HAQ. 
PE and LME3 estimated the best results with around 
−20% bias. LOCF and LE cannot be used at baseline 
since no prior data are available. For missing 6, 12 and 
24 months values, LOCF consistently overestimated the 
true values, while LFE underestimated them, the abso-
lute bias decreasing for longer follow-ups. Among the 
methods using data points before and after the missing 
values, NAO was the most accurate. LME3 overestimated 
the true values, with biases below 10% in absolute value 
at 12 and 24 months. MICE also displayed small biases, 
consistently below 10%.
Compared with imputed missing DAS28, imputed HAQ 
values presented similar relative bias (online supplemen-
tary table S2). Varying the proportion of missingness 
between 10% and 90% at follow-up didn’t affect the bias 
of the imputed values. It resulted in a linear relation 
between the bias of the mean outcome calculated over 
the whole dataset and the percentage of missing value 
(online supplementary figure S3), since an increase of 
missing value increments the amount of biassed imputed 
value entering the calculation of the mean value.
These results can be explained by the mean temporal 
shape of the main outcomes (online supplementary 
figure S4 for DAS28). With appropriate treatment, these 
outcomes begin by improving sharply in the first few 
months after treatment initiation, then they tend to level 
off until the outcomes reach a plateau.31–35 At earlier time 
points, LOCF tends to overestimates the imputed values, 
as values before the follow-up tend to be higher than 
values at later follow-up times. The convex shape of this 
decrease also explains the underestimation of the LFE 
imputation, as the outcome deviates from a local linear 
approximation (see online supplementary figure S5). PE 
and LME3 probably perform best for missing baseline 
values because they fit more adequately the initial steeper 
change compared with the other models. Conversely, 
values imputed by LME3 and PE at 6 and 12 months are 
overestimated because of the influence of the higher 
baseline values. Imputed values at 24 months yielded low 
relative bias for almost all imputation methods because 
the outcome reaches a plateau.
remission and lDa rate
When imputing rates of remission (figure 1, right panel 
and online supplementary table S3) or LDA derived from 
disease activity assessments, a large difference in results 
is observed between the various imputation methods. At 
baseline, LME3 and MICE yield remission rates close to 
the true rates, while the three other methods yield remis-
sion rates overestimated by three times. As LME3 and 
MICE imputed values are narrowly distributed around 
their estimated mean (figure 2, left panel), this does not 
lead to the overrating of small values produced by the 
other methods and so to the overestimation of remission 
rate.
For missing follow-up disease activity data, the narrow 
distribution of LME3 and MICE imputed value creates 
a strong underestimation of the true remission rate 
(figure 2, right panel). The NAO, LE and PE methods on 
the other hand provide an almost unbiased rate of remis-
sion (figure 1, right panel). NAO tends to perform best, 
because the distribution of NAO imputed data is compa-
rable to the true one, whereas PE and LE tend to change 
the imputed value distribution because of their tendency 
to impute negative values (figure 2, right panel). LOCF 
and LFE yield respectively an underestimated and an 
overestimated remission rate with similar absolute differ-
ence (figure 1), in line with their observed tendency to 
respectively overproduce high and LDA values (figure 2).
The narrowing of the distribution of LME3 imputed 
values find its root in the mixed effect part of the regres-
sion, because it supposes that the polynomial coeffi-
cients are normally distributed across the patients, thus 
artificially reducing the range of allowed values. This is 
confirmed by the fact that PE, which is similar to LME3 
but considers each patient individually, does not show 
this artefact (figure 2). The results for LDA yield results 
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Figure 2 Distribution of disease activity score based on 28 
joints values imputed with last observation carried forward 
(LOCF), linear forward extrapolation (LFE), nearest available 
observation (NAO), linear extrapolation (LE), polynomial 
extrapolation (PE), linear mixed effect cubic regression 
(LME3) and multiple imputation by chained equation (MICE), 
for two different follow-up (t=0 and t=12 months), 1000 
imputations of 60% of data missing completely at random at 
follow-up. Black plain area is the true distribution, and colour 
lines are interpolations of the imputed dataset’s distribution. 
The vertical line corresponds to the threshold of remission 
rate.
Figure 3 Mean disease activity score based on 28 joints 
(left panel) and corresponding remission rate (right panel) of 
the data panel where the 60% of data missing at random at 
follow-up were handled with complete case analysis (CCA), 
last observation carried forward (LOCF), linear forward 
extrapolation (LFE), nearest available observation (NAO), 
linear extrapolation (LE), polynomial extrapolation (PE), linear 
mixed effect cubic regression (LME3) and multiple imputation 
by chained equation (MICE). Error bars are the standard 
errors calculated over the 1000 simulation samples. LFE and 
LOCF estimation are missing for t=0 since these methods 
use previous values, which do not exist at baseline. Black 
horizontal lines represent the true values for each follow-up.
qualitatively similar to the remission simulations (see 
online supplementary figure S6 and online supplemen-
tary table S3), confirming our previous conclusions for 
remission rates.
data MAR
Overall, results were generally similar when missing data 
patterns depended on covariates. There are two main 
differences. MICE, which requires MAR data and not 
MCAR, performs better, but still underestimates true 
remission rates by at least 10% at any follow-up visits 
(figure 3). The CCA applied on MAR data leads to biassed 
estimation of the remission rate, the bias reaching 12% at 
2-year follow-up. Imputed mean value, remission rate or 
LDA by other imputation methods are not or only slightly 
affected by attrition bias, even though they do not explic-
itly take into account the covariates. This is certainly due 
to the fact that these methods use previous or subsequent 
measures of the outcome, which depend in part on the 
covariates, and can thus serve as proxy measures of the 
covariates influencing missing data.
sensitivity analysis
In order to test how these results are impacted by the 
proximity of available data near follow-up, we repeated 
the analysis on DS1 with varying ranges of the deletion 
time windows when creating missing data. The results are 
presented for MAR in online supplementary figure S7 
for the mean value, and online supplementary figure S8 
for the remission rate. This sensibility study demonstrates 
that LOCF and LFE are most affected by the size of the 
deletion time window around the visits. When increasing 
the deletion time windows, the bias of imputed values 
increases, since the available time points are further away 
in time (online supplementary figure S5).
In the sensitivity analysis of MICE parameters, the 
change in imputation method, number of imputed data 
sets or iteration number did not affect qualitatively the 
results presented.
A summary of the different results is presented in 
table 1.
dIsCussIOn
This simulation study based on real world data allows to 
compare the consequences of a wide range of strategies 
when dealing with missing values for function or disease 
activity in large registers. However, many methods have 
been proposed and this simulation study does not test all 
of them.25 36 The use of CCA can lead to bias greater than 
10% in estimating the remission rate for follow-up supe-
rior to 1 year. Results for LFE indicates that it should be 
employed only for follow-up at 2 years or more, in agree-
ment with previous results,21 and that LOCF should be 
proscribed.37 For other follow-up times, methods consid-
ering data both before and after follow-up should be 
preferred. Complex methods accounting for the whole 
population such as LME3 and MICE perform well in 
imputing the mean value of the outcome but can induce 
changes in the value distribution of the imputed vari-
able, causing considerable bias when estimating derived 
response rates. The biases of the imputed values are 
mainly due to the imputation method itself and the evolu-
tion in time of the outcome, and thus are not affected by 
the attrition bias nor by the amount of missing data at 
follow-up.
Although MICE becomes more popular,15 38 the misspec-
ification of the model and the violation of underlying 
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Table 1 Summary of the main findings for each imputation method considered
Method
Imputed mean disease activity Imputed remission rate
Effect of random 
missingness
Sensitivity to 
quantity of data 
around follow-upBaseline Follow-up Baseline Follow-up
LOCF Unusable Over-estimated Unusable Under-estimated None Yes
LFE Unusable Under-estimated Unusable Over-estimated None Yes
NAO Strong under-
estimation
Close to 
unbiased
Strong over-
estimation
Close to unbiased None Small
LE Strong under-
estimation
Close to 
unbiased
Strong over-
estimation
Slightly biassed None Small
PE Strong under-
estimation
Slightly biassed Strong over-
estimation
Close to unbiased None Yes
LME3 Strong under-
estimation
Close to 
unbiased
Close to unbiased Strong under-
estimation
None No
MICE Strong under-
estimation
Close to 
unbiased
Close to unbiased Strong under-
estimation
Reduction of bias 
of remission
No
LE, linear extrapolation; LFE, linear forward extrapolation; LME3, linear mixed effects cubic regression; LOCF, last observation carried 
forward; MICE, multiple imputation by chained equation; NAO, nearest available observation; PE, polynomial extrapolation.
assumptions such as conditional normality can lead to 
severe pitfalls39 40 and the choice of covariate is critical.41 
Other studies reported changes in distribution of data 
imputed with MICE.42 Though we included in the model 
several co-variates, they did not manage to reproduce the 
variability of the disease activity, even when they were the 
variables used to generate missing data. A possibility to 
overcome this problem could be the use of algorithms 
considering adjacent time.43 Indeed, missing data impu-
tation of longitudinal data with unequal time steps is a 
very active area of research.43 But given the complexity 
of such method and the good results of simpler methods, 
MICE should be restricted to its use in regression models, 
where it has been widely studied and proven useful.11 44 45
There are strengths and limitations to the present 
study. The results of our study are supported by the use 
of data stemming from a large international collection 
of register of RA patient. Using purely simulated data 
may lead to excessively good results of the models due 
to having model assumptions being met too perfectly 
by the artificial data. Good care was taken for the simu-
lation dataset to reproduce a disease duration and visit 
frequency structure, as well as pattern of missing data 
(MAR data), similar to the entire collection of register 
containing more than 49 000 patients. The large range of 
imputation techniques considered and the detailed effect 
of their use on both the mean value of disease activity and 
the remission rate is another asset of the present study. 
The results presented are reinforced by their robustness 
to the different sensitivity analysis performed.
However, using real data is also a limitation. Indeed, the 
main limitation of the present study is the use of a specific 
type of observational data coming from patients with 
active or established RA treated with biological DMARD. 
Although the results may be generalisable to cohorts with 
patients presenting a similar evolution of disease activity 
in time, they cannot be extrapolated without further 
studies to other types of cohort presenting a different 
pattern of disease activity over time, such as early arthritis 
cohorts or remission cohorts. Furthermore, our study 
only considers missing data of patients still available in 
the cohort, and does not tackle the difficult problem of 
lost to follow-up data, for which imputation may not be 
the proper approach.46
The overall results of this simulation study suggest that 
imputation of function and disease activity assessments 
at baseline is best performed with linear mixed effects 
models with a cubic effect of time (LME3) or multiple 
imputation (MICE), and for imputation at follow-up 
times best with the nearest available observation (NAO).
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